Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Daniel Kulp has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is located within 1 distinct art unit. The presence of 1 pending action indicates a focused prosecution stage for the current biotechnology applications. Practitioners will interact with a single point of contact at the patent office for this specific matter.
GRIZER, CASSANDRA SENN is the busiest examiner for the portfolio, currently managing the 1 pending office action. Since the busiest examiner pending count is 1, the entire active workload is concentrated under this individual. The 1 distinct art unit involved suggests that the technical subject matter is limited to a specific classification within Biotechnology & Pharmaceuticals. This concentration of 1 pending action under GRIZER, CASSANDRA SENN allows for a targeted prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRIZER, CASSANDRA SENN | 1 | 70.0% | +48.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18856345 | STABILIZED SPIKE PROTEIN AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | GRIZER, CASSANDRA SENN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18856345 | STABILIZED SPIKE PROTEIN AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | GRIZER, CASSANDRA SENN | 1672 | §112 | Non-Final OA | — | Pending | Oct 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDaniel Kulp has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Cassandra Senn Grizer has the most, with 1 of Daniel Kulp's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
